文献速递湿疹皮炎与荨麻疹

特应性皮炎新型系统治疗安全性的可扩展评估方法:序贯监测系统首个分析周期

A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System.
PubMed 文献 · J Invest Dermatol · 2024-10-01

本研究建立了一个数据和分框架,用于在临床实践中对特应性皮炎新型免疫调节药物进行序贯倾向评分匹配队列的安全性比较。首个分析周期(2021年12月至2023年2月)比较了269例Jak抑制剂起始者与2650例IL-4/IL-13抑制剂起始者,发现180天内门诊感染风险比为1.50(95%CI 0.96-2.33),痤疮风险比为2.29(95%CI 0.96-5.46),均无统计学显著性。

要点

  • 序贯监测系统可随每年数据刷新扩大样本量,提供特应性皮炎药物安全性证据。
  • 首个分析周期中Jak抑制剂与IL-4/IL-13抑制剂相比,门诊感染和痤疮风险无显著差异。
  • 倾向评分匹配后患者特征均衡良好,支持比较的可靠性。

核心结论

  • 序贯监测系统能够基于临床实践数据生成特应性皮炎免疫调节药物安全性的及时证据。

研究设计与样本

  • 研究设计为序贯倾向评分平衡队列,随每年数据刷新扩大样本量。
  • 首个分析周期(2021年12月至2023年2月)纳入269例Jak抑制剂起始者和2650例IL-4/IL-13抑制剂起始者。

主要发现

  • 180天内门诊感染发生率:Jak1抑制剂起始者18%,dupilumab/tralokinumab起始者12%,风险比=1.50(95%CI 0.96-2.33)。
  • 痤疮风险:Jak抑制剂起始者7%,IL-4/IL-13抑制剂起始者3%,风险比=2.29(95%CI 0.96-5.46)。

关键数值与推荐

  • 识别了9个健康结局以及结膜炎作为阳性示踪结局。
  • 初始治疗比较为dupilumab(IL-4/13抑制剂)或tralokinumab(IL-13抑制剂) versus abrocitinib/upadacitinib(Jak抑制剂)。

临床怎么用

  • 临床实践中可参考该监测系统持续评估特应性皮炎新型系统治疗的安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted systemic immune-modulating drugs to treat atopic dermatitis were highly efficacious in randomized trials. Trials with limited number of subjects leave questions about their safety. We describe a data and analytics structure for the production of timely, high-quality evidence on the comparative safety of recently approved immune-modulating drugs in patients with atopic dermatitis in clinical practice. We established a series of sequential propensity score-balanced cohorts that grow in size with each annual data refresh. Nine health outcomes of interest plus conjunctivitis as a positive tracer outcome were identified. The initial treatment comparison was dupilumab, an IL-4/13 inhibitor, or tralokinumab, an IL-13 inhibitor, versus abrocitinib/upadacitinib, both Jak inhibitors. The first analysis cycle (December 2021-February 2023) compared 269 patients initiating Jak inhibitors and 2650 initiating IL-4/IL-13 inhibitors. Patient characteristics were well-balanced after propensity score matching. Outpatient infections within 180 days occurred in 18% of Jak1 inhibitor initiators versus 12% of dupilumab/tralokinumab initiators (risk ratio = 1.50, 95% confidence interval = 0.96-2.33), whereas acne risks were 7 versus 3%, respectively (risk ratio = 2.29, 95% confidence interval = 0.96-5.46). This sequential monitoring system will produce essential knowledge on the safety of immune-modulating drugs to treat atopic dermatitis on the basis of its growing study size of patients observed in clinical practice.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Schneeweiss MC, Glynn RJ, Wyss R, et al. A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System. J Invest Dermatol. 2024. PMID: 39362623. doi:10.1016/j.jid.2024.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。